Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoproteinb levels

HIGHLIGHTS

• who: Adam J. Nelson and collaborators from the Victorian Heart Institute, Monash University, Clayton, VIC, Australia have published the research: Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering ApolipoproteinB Levels, in the Journal: (JOURNAL) of 28/07/2022
• what: The aim of the present review is to provide an up-to-date understanding of CETP inhibition and its relationship to ASCVD risk reduction. The aim of this review is to describe the data supporting the hypothesis that CETP inhibitors have the capacity to reduce MACE as a consequence of their effects . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.